#NORML #News @WeedConnection

Share This

Clinical Trial: Cannabis-Infused Tea Mitigates Pain in Patients With Fibromyalgia

Potenza, Italy: The daily consumption of cannabis-infused tea is associated with decreased pain and improved quality of life in fibromyalgia (FM) patients, according to clinical trial data published in the Journal of Clinical Medicine.

Italian scientists assessed the efficacy of cannabis flower (22 percent THC | 1 percent CBD) steeped in tea in a cohort of 30 patients with refractory FM. Patients consumed the infused tea daily for six months.

Patients’ median pain ratings fell from 8 (on a numerical scale of 1 to 10) to 4 during the trial. Study participants also reported improvements in physical and mental health. None of the patients who completed the trial reported any adverse side effects from cannabis.

The study’s authors concluded: “Cannabinoids may represent an effective alternative to conventional pharmacological therapy for reducing pain and mind disorders in FM subjects. Further investigations like randomized, placebo-controlled clinical trials are needed to corroborate these findings.”

Fibromyalgia patients frequently self-report using cannabis to successfully manage symptoms of the disorder. Observational data published last year reported that FM patients who consume medical cannabis preparations reduce their need for prescription opioids.

Full text of the study, “Is a low dose of cannabis effective for treating pain related to fibromyalgia? A pilot study and systematic review,” appears in the Journal of Clinical Medicine.

Study: Patients Suffering From GI Disorders Report Sustained Improvements With Cannabis

Philadelphia, PA: Patients with refractory gastrointestinal (GI) symptoms report sustained improvements following their use of cannabis, according to data published in the journal Medical Cannabis and Cannabinoids.

A team of investigators affiliated with Thomas Jefferson University in Philadelphia assessed changes in patients’ GI symptoms (e.g., anorexia, nausea, vomiting, stomach pain) at 30 days, six months, and at 12 months. Study participants consumed a variety of cannabis formulations, including extracts and flower.

“In each survey, participants reported a significant decrease in GI symptom severity when using medical marijuana versus when not using medical marijuana,” researchers reported.

The study’s authors concluded: “This is the first study to examine MMJ’s [medical marijuana’s] longitudinal effects on GI symptoms in patients with refractory GI and non-GI MMJ-certified conditions. Overall, participants reported significant, enduring moderate GI symptom relief when using MMJ. ... Additional studies ... should assess the effects of different CBD/THC ratios, dosing, and methods of administration on GI symptom relief.”

The findings are consistent with those of several other studies showing that cannabis is associated with improved symptom management in patients with Crohn’s disease, IBS, gastroparesis, inflammatory bowel disease, and other GI-related conditions.

Full text of the study, “Relief in gastrointestinal symptoms with medical marijuana over 1 year,” appears in Medical Cannabis and Cannabinoids.

Clinical Trial: Medical Cannabis Treatment Mitigates Symptoms in Autistic Children

Haifa, Israel: Preparations of CBD-rich cannabis reduce anxiety and other autistic symptoms in children, according to data published in the journal Cannabis and Cannabinoid Research.

Israeli scientists assessed the efficacy of CBD-dominant cannabis extracts in a cohort of 65 children (ages 5-12 years) with autism. Study participants consumed customized doses of cannabis extracts for six months.

Researchers reported: “We observed significant differences in the autistic children’s overall anxiety and in some anxiety subtypes. Significant improvements were observed in RRBI [restricted and repetitive behaviors and interests], including the total score, and specifically in compulsive, ritualistic, and sameness behaviors.”

The study’s authors concluded: “Our study suggests positive implications for CBD-rich cannabis treatment in alleviating anxiety and RRBI symptoms in autistic children. ... We strongly recommend further double-blind, placebo-controlled studies using standardized assessments to validate these findings.”

The findings are consistent with those of numerous other studies showing that cannabinoid treatment provides symptom improvements in children with autism. Observational studies have also shown that the use of cannabis can provide benefits to adults with autism.

Full text of the study, “Effects of medical cannabis treatment for autistic children on anxiety and restricted and repetitive behaviors and interests: An open-label study,” appears in Cannabis and Cannabinoid Research.

Survey: Most Consumers Say That Marijuana Reduces Their Need for Prescription Painkillers

Columbus, OH: Nearly three-quarters of cannabis consumers say that the use of marijuana mitigates their need for prescription pain medications, according to survey data compiled by researchers affiliated with Ohio State University’s Moritz College of Law.

Of the approximately 3,500 consumers surveyed, 78 percent agreed with the statement, “Using marijuana has reduced my need to use prescription painkillers.” Twenty-seven percent of respondents also said that cannabis reduced their use of other illegal drugs.

The survey’s findings are consistent with those of numerous others reporting that those who consume cannabis frequently reduce their use of opioid medications and other controlled substances.

Specifically, a 2022 study published in the journal Health Economics reported that marijuana legalization is associated with “significant reductions in the volume of prescriptions within the drug classes that align with the medical indications for pain, depression, anxiety, sleep, psychosis, and seizures.” A more recent assessment of Canadian medical cannabis patients finds that marijuana access is associated with decreasing use of opioids, alcohol, tobacco, and other controlled substances.

Full text of the study, “Using marijuana to reduce the use of prescription painkillers and other illicit drugs: Results from an Ohio survey,” is available from SSRN.

#NORML #News @WeedConnection

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube

#FollowFriday @TheTrueOGReport #ComingSoon @WeedConnection

Share This
* New Show NQ @TheTrueOGReport *

* READ & Click & READ & Click *

:: Creator @ WC @ RR Productions ::
:: Follow @RussellRope For Updates ::

#OG @RussellRope #Creator @WeedConnection

:: Join The Revolution ::
:: Read & Take Action ::
:: True OG Stories @ RR ::
:: SUPREME #LegalTrillOG ::

----------------------------------

:: Media Marketing Services @ RRP ::

:: Connect | ADVERTISE | Work | Submit ::

:: Subscribe | Follow | Share | Like | Support ::

:: #FreeTheWeed @WeedConnection ::

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube @WeedConnection @ Yelp @WeedConnection @ Google+ @WeedConnection @ instaGram

weedconnection.com

#International #Business @WeedConnection

Share This

New WC Franchise in Development @ RRP OG LLC
All Advertising/Media Services Will Be Honored
10-50% DiScOuNt :: Connect / Select You Plan

. . . .

Ask about our current promotion, which is a free listing with purchase of any other service @WeedConnection. Recently started rebuilding our global database and added a new/temp delivery section to our directory. Send us an email to submit any current information. Click here for listing and advertising information. The directory is a huge project that requires maintenance. We still have big plans for future development and production. Join(t) the team as a regional manager, college intern, street team member, or click here for a list of other open positions. Support, subscribe, follow, share, like, and mention growing cannabis business @WeedConnection


#iNTERNATiONAL #Directory

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube @WeedConnection @ Yelp @WeedConnection @ Google+ @WeedConnection @ instaGram

weedconnection.com

#NORML #News @WeedConnection

Share This

Clinical Trial: Hemp-Derived CBG Associated With Decreased Stress, Improved Memory

Pullman, WA: The consumption of the cannabinoid cannabigerol (CBG) is associated with reduced feelings of stress and anxiety, according to placebo-controlled data published in the journal Nature: Scientific Reports.

Researchers with Washington State University and the University of California, Los Angeles, assessed the use of a hemp-derived 20 mg CBG tincture versus placebo in 34 health volunteers. Most of the study’s participants had no prior experience with CBG.

Investigators reported that CBG, but not the placebo, was associated with significant enhancements in participants’ verbal memory as well as decreases in their feelings of stress and anxiety. CBG was not associated with either intoxicating or performance-impairing effects.

The study’s authors concluded: “The present study represents the first human clinical trial to examine the acute effects of CBG on anxiety, stress, and mood. Results of this double-blind, placebo-controlled, cross-over field trial indicate that 20 mg of hemp-derived CBG reduces subjective ratings of anxiety and stress in healthy cannabis-using adults in the absence of motor or cognitive impairment, intoxication, or other subjective drug effects (e.g., heart palpitations, dry mouth). Additional research is needed to corroborate these novel findings as well as to extend them to a clinical population of patients with anxiety disorders.”

In preclinical models, CBG has been shown to possess analgesic, anti-inflammatory, anti-cancer, and blood pressure-reducing properties. Survey data published in 2021 reports that consumers who prefer CBG-dominant varieties of cannabis perceive it to be effective at managing anxiety, chronic pain, depression, and insomnia.

Full text of the study, “Acute effects of cannabigerol on anxiety, stress, and mood: A double-blind, placebo-controlled, crossover, field trial,” appears in Nature: Scientific Reports.

Study: Cannabis Use Inversely Associated With Metabolic Syndrome in Younger Adults

Miami, FL: Young adults who consume cannabis are far less likely than never users to suffer from metabolic syndrome (MetS), according to data published in the American Journal of Open Medicine. Metabolic syndrome is a cluster of risk factors, including unhealthy cholesterol levels and abdominal fat, that are linked to an increased risk of heart disease and adult-onset diabetes, among other serious health consequences.

Researchers affiliated with the University of Miami assessed the relationship between cannabis use and MetS in a nationally representative cohort of nearly 4,000 young adults (ages 18 to 25).

Consistent with prior studies, current cannabis consumers had lower waist circumference and lower BMI compared to controls.

Overall, current cannabis consumers possessed 42 percent lower odds of having MetS. Non-Hispanic Blacks, who acknowledged consuming cannabis at higher rates than other subjects, were least likely to suffer from metabolic syndrome.

“Current cannabis users had a lower prevalence of MetS, predominantly noted among NHB [non-Hispanic Blacks], the group with the highest prevalence of current cannabis use,” the study’s authors concluded. “Future prospective studies are warranted to examine the role of specific cannabinoids on MetS by race/ethnicity.”

Observational studies have previously reported an association between cannabis use and lower blood pressure and decreased rates of obesity.

Full text of the study, “Prevalence of metabolic syndrome among emerging adult cannabis users by race/ethnicity: Analysis of the 2009-2018 National Health and Nutrition Examination Surveys,” appears in the American Journal of Open Medicine.

Analysis: Nearly 50,000 People Have Been Deported for Violating Marijuana Laws

New York, NY: Nearly 50,000 non-citizens have been deported over the past decades for violating marijuana possession laws, according to data compiled by the advocacy groups Human Rights Watch and the Drug Policy Alliance.

Researchers analyzed federal deportation data for the years 2002 to 2021. During this time, they estimated that federal officials deported approximately 156,000 non-citizens whose most serious conviction was illicit drug possession. Nearly one-third of those offenders (47,000) were deported for violating marijuana possession laws.

The report’s authors further acknowledged that, in some instances, non-citizens are being deported for marijuana-related activities that are no longer criminalized by state and local jurisdictions.

“The US federal government has thus far been unwilling to revise federal immigration law to match current public sentiment on drugs,” authors wrote. “There is no statute of limitations in federal law on deportation after a criminal conviction. Many immigrants are still being deported for convictions from the late 1980s and early 1990s, sometimes for conduct that is no longer a crime under state law.”

In total, nearly one out of every five immigrants deported was removed from the country for a drug-related conviction.

The full text of the report, “Disrupt and Vilify: The War on Immigrants Inside the US War on Drugs,” is available from Human Rights Watch.

Physicians Group Calls for Cannabis Decriminalization

Washington, DC: The American College of Physicians, which represents the interests of more than 160,000 internal medicine physicians, has issued a new policy paper calling for the decriminalization of activities involving the personal possession of cannabis.

The organization recommends decriminalization “to help address systemic inequities and promote treatment-focused alternatives to criminal penalties for substance use disorders.”

Specifically, the ACP states, “[The] possession of small amounts of cannabis for personal use be decriminalized.” It also calls for additional resources for agencies involved in regulating state-legal cannabis products and for greater training for doctors and other health professionals.

“Cannabis content should be incorporated into substance use curricula at all levels of physician education,” the group states. Healthcare professionals in the United States and abroad – including nurses, pharmacists, clinicians, and nurse practitioners -- consistently acknowledge that they are inadequately trained to counsel patients on matters specific to medical cannabis.

A complete list of the ACP’s recommendations appears in the journal, Annals of Internal Medicine.

Oklahoma: Medical Cannabis Use While Pregnant Doesn’t Constitute Child Neglect, Appellate Court Rules

Oklahoma City, OK: Authorized patients who consume medical cannabis while pregnant cannot be criminally prosecuted for child neglect, according to a ruling handed down last week by the Oklahoma Court of Criminal Appeals.

The Court’s majority determined that the felony crime of child neglect only applies to instances where a child is exposed to “illegal drugs.” Justices opined that the use of cannabis, when authorized by state-licensed physicians, does not meet the statutory definition of an illegal drug.

The medical use of cannabis has been legal in Oklahoma since 2018.

“The terms ‘controlled dangerous substance’ and illegal drugs are not synonymous,” justices wrote. “The former includes hundreds of prescription drugs which, like marijuana, are lawful to possess only with a prescription or other legal authorization. ... It is undisputed that [the defendant] had one. ... Hence, ... an expectant mother’s licensed possession and use of medical marijuana would not trigger an automatic finding of neglect for failure to protect her unborn child from exposure to illegal drugs because to her, marijuana, is not an illegal drug.”

They concluded: “Like it or not, in Oklahoma, marijuana, like all of these other controlled substances, may now be either a legal or an illegal drug, depending upon whether a person has legal authorization to possess and use it. … For us to find that [the defendant’s] marijuana use, fully authorized by her medical marijuana card, became illegal due to her pregnancy, would require us to rewrite the statute in a way we simply do not think is appropriate for courts to do.”

Two justices dissented in the case.

The majority’s opinion is consistent with that of a recent Arizona Appellate Court ruling, which similarly determined that a pregnant mother’s physician-authorized use of marijuana did not meet the statutory definition of child neglect. That decision was ultimately upheld by the Arizona Supreme Court.

In recent years, prosecutors in Alabama and Oklahoma have pursued criminal prosecutions of several women for engaging in the use of cannabis during their pregnancy.

The case is Oklahoma v Aguilar.

#NORML #News @WeedConnection

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube

#FollowFriday @ClassySavageArt #NFTs @WeedConnection

Share This
Get Sum
Merch & NFTs
@ Classy Savage
Hybrid ( Ai >< OG ) Art

#ClassySavage #Art @WeedConnection

* New Show NQ @TheTrueOGReport ** READ & Click & READ & Click *

:: Creator @ WC @ RR Productions ::
:: Follow @RussellRope For Updates ::

#OG @RussellRope #Creator @WeedConnection

:: Join The Revolution ::
:: Read & Take Action ::
:: True OG Stories @ RR ::
:: SUPREME #LegalTrillOG ::

----------------------------------

:: Media Marketing Services @ RRP ::

:: Connect | ADVERTISE | Work | Submit ::

:: Subscribe | Follow | Share | Like | Support ::

:: #FreeTheWeed @WeedConnection ::

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube @WeedConnection @ Yelp @WeedConnection @ Google+ @WeedConnection @ instaGram

weedconnection.com

#NORML #News @WeedConnection

Share This

Prenatal Cannabis Exposure Not Associated With Elevated Risk of Autism

Atlanta, GA: Children exposed to cannabis in utero possess no elevated risk of suffering from autism spectrum disorder (ASD), according to data published in the journal Autism Research.

Researchers affiliated with Emory University, John Hopkins, and Harvard assessed the relationship between prenatal cannabis exposure and ASD in a sample of 11,570 children.

Investigators reported no link between cannabis exposure and ASD after controlling for relevant covariates, particularly tobacco consumption.

They concluded, “In a large sample and measuring ASD traits continuously, there was no evidence that prenatal cannabis exposure increases the risk for ASD. ... Although no associations were found with ASD outcomes, prenatal cannabis exposure may still be associated with other facets of child development and behavior that were outside of the scope of this study, such as attention and cognition.”

Studies assessing the relationship between in-utero cannabis exposure and various neonatal outcomes, such as birth weight, have yielded inconsistent results. However, longitudinal data suggests that cannabis exposure is rarely associated with adverse neurodevelopmental consequences, finding, “Although there is a theoretical potential for cannabis to interfere with neurodevelopment, human data drawn from four prospective cohorts have not identified any long-term or long lasting meaningful differences between children exposed in utero to cannabis and those not.”

Full text of the study, “Examining the association between prenatal cannabis exposure and child autism traits: A multi-cohort investigation in the environmental influences of child health outcome program,” appears in Autism Research.

Study: Consumers Report Improvements in Anxiety, Depression Following Cannabis Use

Fort Myers, FL: Consumers report reductions in their feelings of anxiety and depression immediately following their marijuana use, according to data published in the journal Cannabis.

Investigators affiliated with Florida Gulf Coast University assessed the short-term effects of cannabis on symptoms of anxiety and depression in a cohort of 418 subjects. Study participants self-administered cannabis at home and reported symptom changes in real-time on a mobile software application. Researchers evaluated data from 9,966 sessions.

The study’s authors determined, “[B]oth depression and anxiety symptoms significantly decreased after cannabis use in general; results at the user level of analysis showed that the majority of users experienced positive relief outcomes.”

They concluded: “[These results] replicate previous work which has shown decreases in depression and anxiety symptomatology following real-time cannabis consumption. ... Our results ... speak to the potential of cannabis to combat acute depression and anxiety with a rapid onset of self-reported relief.”

Survey data finds that those who consume cannabis for purposes of self-medication most frequently report doing so to address pain, anxiety, sleep disturbances, and depression.

Full text of the study, “Using smartphone technology to track real-time changes in anxiety/depression symptomatology among Florida cannabis users,” appears in Cannabis.

Meta-Analysis: Cannabis-Induced Psychosis Rare in Those Without Pre-Existing Mental Health Conditions

Lausanne, Switzerland: Cannabis consumption rarely triggers episodes of acute psychosis in those who do not have a pre-existing psychiatric disorder, according to the results of a meta-analysis published in the journal Nature: Mental Health.

An international team of researchers from Switzerland and the United Kingdom reviewed the relationship between marijuana use and cannabis-associated psychotic symptoms (CAPS) in 162 studies involving over 210,000 cannabis consumers.

Researchers reported that the risk of psychosis “appears most amplified in vulnerable individuals,” particularly those with “pre-existing mental health problems” such as bipolar disorder. By contrast, they acknowledged, “[N]either young age of onset of cannabis use nor high-frequency use of cannabis or the preferred type of cannabis (strains high in THC, strains high in CBD) was associated with CAPS.”

Overall, they estimated that 0.5 percent of those who consume cannabis may experience a psychotic episode during their lifetime. That percentage mirrors estimates published in a prior study involving 233,000 European marijuana consumers. The authors of that study concluded, “Rates of CAPS as observed here are comparable to rates of other drug-induced psychosis, such as alcohol-associated psychosis (around 0.4 – 0.7 percent).”

The studies’ findings push back against claims that marijuana exposure is a frequent trigger for psychosis and other mental health disorders.

Full text of the study, “Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental, and medical research.

Survey: Patients Say Cannabis Effectively Treats Their Musculoskeletal Pain

Toronto, Canada: More than one in five patients with chronic musculoskeletal pain (MSK) report having used cannabis to manage their symptoms and 90 percent of them perceive it to be effective, according to data published in the Journal of Cannabis Research.

Canadian researchers surveyed 629 patients with chronic MSK pain. Twenty-three percent acknowledged having used cannabis therapeutically. Over 90 percent of consumers said that it was either “very,” “somewhat,” or “slightly” effective at managing their pain, improving their sleep, and reducing anxiety-related symptoms. More than half (57 percent) perceived cannabis to be more effective than other analgesic medications, and 40 percent acknowledged decreasing their use of traditional pain medications following their use of cannabis.

The study’s authors concluded: “One in five patients presenting to an orthopaedic surgeon with chronic MSK pain are using or have used cannabis with the specific intent to manage their pain, and most report it to be effective. ... Future double-blind placebo-controlled trials are required to understand if this reported efficacy is accurate, and what role, if any, cannabis may play in the management of chronic MSK pain.”

Survey data published last month reported that one in four cannabis consumers use it primarily to achieve pain relief.

Full text of the study, “Understanding the epidemiology and perceived efficacy of cannabis use in patients with chronic musculoskeletal pain,” appears in the Journal of Cannabis Research.

#NORML #News @WeedConnection

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube

#SocialMedia #Revolution @WeedConnection

Share This

* Connect @RussellRope *
* New WC Social Links List NQ *

:: FYi FB/iG Terminated WC Accts Again ::
:: No Just Cause FB iS Run By Sociopaths ::
:: They iNvested iN Criminal Competition ::

:: See Fed RiCO Lawsuit @ RR ::

. . . .

:: Join Us For A Hollyweed Sesh ::
:: Subscribe, Follow, Like, Add, Share ::

@WeedCONNECTiON

#SocialMedia @WeedConnection

SOCIAL:
twitter.com/weedconnection
instagram.com/weedconnection
facebook.com/weedconnection
myspace.com/weedconnection420
youtube.com/weedconnection420

BUSINESS:
weedconnection.com
weedconnection.com/advertise

CREATOR:
@RussellRope @ russellrope.com/blog

#Support Your #OG(s)
#LinkUP @WeedConnection

@WeedConnection .com



Email:

#FreeTheOG
#FreeTheWeed
Fund WC++

Read RR True Story
Connect | ADVERTISE | Work | Submit
Subscribe | Follow | Share | Like | Support

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube @WeedConnection @ Yelp @WeedConnection @ Google+ @WeedConnection @ instaGram

weedconnection.com